ASRT vs OM

ASRT's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and inconsistent earnings performance. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given negative earnings and high revenue volatility. Despite strong revenue growth (69.4% YoY) and a low price-to-sales ratio (0.54), the company trades at a significant discount due to deep operational losses and poor capital efficiency. Insider selling activity and a 5-year price decline of 80.4% further undermine confidence. The stock's current valuation appears unsustainable without a clear path to sustained profitability.

Outset Medical exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. Despite a strong current ratio of 6.67 suggesting short-term liquidity, the company suffers from catastrophic long-term price erosion (-99.5% over 5 years) and negative revenue growth. The combination of deep negative profit margins (-68.34%) and consistent insider selling suggests a lack of confidence in a turnaround. While analysts maintain a 'buy' rating with a $9.00 target, the deterministic data points to a high risk of further capital impairment.